Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Prognostic factors of overall survival in patients after liver metastasectomy from breast cancer. (only multivariate Cox regression analyses)

From: Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature

Study Hoffman10 Abott15 Walsum12 Zegarac13 Dittmar16 Weinrich9 Vertriest14
Number 41 86 32 32 34 21 27
Duration 1999–2008 1997–2010 1991–2011 2006–2009 1997–2010 2001–2007 1996–2013
Median overall survival (months) 58 57 55 37 36 53 116
5-year overall survival (%) 48.4   37   28 33 78
Median disease-free survival (months) 34 14.2 11 22.5    
5-year disease-free survival (%) 31   19     36
Characteristics of primary BC        
ER status   p = 0.009   p < 0.05    
  (pos)   (pos)    
Lymph node status     p < 0.05    
    (neg)    
Tumor size     p < 0.05    
    (<3 cm)    
Grading       p = 0.0059  
Stage        p = 0.03
       (Stages I–II)
Characteristics of LM and LM treatment        
Age      p = 0.004   
     (<50)   
Period from BC to LM p = 0.0097    p < 0.05    
(>24 months)    (>24 months)    
Number of LM    p < 0.05 p < 0.01    p = 0.04
   (1 vs >1) (1 vs >1)    (1 vs >1)
HER2 status      p = 0.010   
     (pos)   
Absence of extrahepatic tumor      p = 0.042   
Response to preoperative chemotherapy   p = 0.003      
  (good response)      
Resection margins p = 0.0015       
(R0 vs R1/2)       
  1. BC breast cancer, ER estrogen receptor, LM liver metastasis, HER2 human epidermal growth factor receptor 2, neg negative, pos positive, R0 complete microscopic resection, R1 microscopic residual disease, R2 macroscopic residual hepatic or extrahepatic disease